Pulmonary hygiene is essential to preventing illness and reducing hospitalizations rates in patients with neuromuscular disorders including DMD, an expert said at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference.
The level of expression of the MTCH2 gene may be involved in the timing and severity of cardiomyopathy in patients with DMD, according to a new study presented at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference.
Patients with Duchenne and Becker muscular dystrophies experience high rates of cognitive learning challenges, according to caregiver assessments.
Results from a phase 2 trial suggest delandistrogene moxeparvovec (SRP-9001) has a biological effect that may be clinically relevant in DMD.
Researchers joined forces to better understand the serious adverse events that occurred during trials evaluating gene therapies to treat DMD.
Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) will take center stage at the first in-person annual gathering of the Muscular Dystrophy Association (MDA) since March 2019.
The Muscular Dystrophy Association (MDA)’s 2022 clinical and scientific conference will be held March 13-16 both virtually and in person at the Gaylord Opryland Resort and Convention Center in Nashville, Tennessee. Registration is now open.